In murine prostate cancer models, Current et al. recently reported that intrasubject variability in PSMA expression, and the frequency of PSMA high-, medium-, or low-expressing cells, caused disparities in therapeutic effectiveness [128]. The gene discussed is FOLH1; the disease is Familial prostate cancer.